IPO Year: 2014
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2025 | $62.00 | Outperform | Raymond James |
| 7/11/2025 | $52.00 | Overweight | Cantor Fitzgerald |
| 6/12/2025 | $78.00 | Overweight | Piper Sandler |
| 5/21/2025 | $65.00 | Outperform | Oppenheimer |
| 5/15/2025 | $55.00 | Buy | BTIG Research |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $62.00
Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $52.00
Piper Sandler initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $78.00
Oppenheimer initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $65.00
BTIG Research initiated coverage of Tvardi Therapeutics with a rating of Buy and set a new price target of $55.00
Fastest customizable press release news feed in the world
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company
On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway anticipated to be sufficient to fund operations into Q4 2026 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for patients with idiopathic
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 60 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company fo
Topline data from the REVERT IPF trial anticipated in 4Q 2025 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3.
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, NY. Details are as follows: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways Format: Fireside Chat Date: Tuesday, May 27, 2025 Time: 11:30 AM ET Jefferies Global Healthcare Conference Format: Corporate P
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that an abstract will be presented at the American Thoracic Society 2025 Annual Conference, which is being held May 16-21 in San Francisco. The abstract highlights the role of STAT3 as a master regulator of idiopathic pulmonary fibrosis (IPF). In preclinical studies, TTI-101, Tvardi's STAT3 inhibitor, suppressed fibrotic markers which are not addressed with currently approved therapies (nintedanib and pirfenidone). Using single-cell RNA sequencing on lung samples
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
SCHEDULE 13G - Tvardi Therapeutics, Inc. (0001346830) (Subject)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
S-1 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K/A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)